

# YOSEMITE STUDY

..for diabetic macular edema



## Diabetic Macular Edema

---

*Phase III, multi-center, randomized, double-masked, active comparator controlled study to evaluate the efficacy and safety of RO6867461 in patients with diabetic macular edema*

*Principal Investigator  
Dr. Matthew Ohr*

### **INCLUSION CRITERIA:**

- At least 18 years of age with type 1 or 2 diabetes mellitus, which is currently treated with insulin or oral agents
- Macular thickening secondary to DME involving the center of the fovea
- BCVA of 73 to 25 letters, inclusive (20/40 to 20/320 approximate Snellen equivalent)
- 

### **EXCLUSION CRITERIA:**

- High-risk PDR in the study eye
- Uncontrolled glaucoma
- IVT anti-VEGF treatment within 3 months prior to Day 1 or any IVT anti-VEGF agents to study eye prior to Day 1
- Treatment with PRP within 3 months prior to Day 1
- Macular laser within 3 months prior to Day 1
- Active cancer within the past 12 months
- Uncontrolled blood pressure (defined as systolic >180 mmHg and/or diastolic >100 mmHg while a patient is at rest)

---

**CONTACT** Havener Eye Institute Research Office • 614-293-5287 • Research@osumc.edu

This research is not being conducted by the Columbus Chalmers P. Wiley Ambulatory Care Center. The research has not been reviewed by the Institutional Review Board of the Chalmers P. Wiley VA. The VA is not responsible for any costs incurred by participating in the research study.